Author + information
- Zhenguang Li,
- Hairong Sun,
- Duanlan Ma,
- Pengfei Wang,
- Jiangshan Zhang,
- Zhancai Yu and
- Jinbiao Zhang
To investigate the changes of plasma lysophosphatidic acid(LPA) or acidic phospholipids (AP) levels in patients with nonvalvular atrial fibrillation (NVAF) or NVAF-associated ischemic stroke and to provide biochemistry evidence to antithrombotic therapy.
The present study examined plasma LPA/AP levels using fresh fetched blood in 235 cases of NVAF who were not receiving any antithrombotic therapy, 119 cases with NVAF-associated ischemic stroke and 120 cases acute cerebral infarction who were not with NVAF enrolled in the LPA and Stroke Prevention Study. Plasma LPA was assayed by measuring its inorganic phosphorus after separation by chromatograph. Meanwhile, the LPA levels during different time point after stroke onset were observed.
LPA levels were significantly increased in all NVAF group comparing with controls (age≤60 years group P<0.01, 61∼76 years group P<0.01, age ≥76 years group P<0.001). In age ≥76 years group, the LPA levels were significantly increased compared with ≤60 years group (P<0.01). Within 24 hours after onset, an elevated LPA levels were seen in NVAF-associated ischemic stroke group (n=119) comparing with lone NVAF or controls (P<0.01, P<0.001). AP levels were significantly increased in both NVAF-associated ischemic stroke group and lone NVAF group comparing with controls (P<0.01). Within 24 hours after onset, an elevated LPA levels were seen in NVAF-associated ischemic stroke group comparing with lone NVAF group or controls. LPA levels in NVAF-associated ischemic stroke group were seen in high lasted 1 week.
He plasma LPA/AP levels were significantly elevated in lone NVAF, acute stage of NVAF-associated ischemic stroke or acute cerebral infarction who were not with NVAF. We suggest that platelet activation may play an important role in the pathogenesis of thromboembolism in NVAF and the measurement of LPA reflects activation of platelets in vivo and may be a useful marker for the diagnosis of thrombosis or prothrombotic states. The time window for antithrombotic therapy to NVAF-associated ischemic stroke would be longer.